The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor. Both drugs have ...

The new indication will be another blow to Praluent’s PCSK9 inhibitor rival Repatha. Both drugs have been fighting it out after they were approved within a few weeks of each other in 2015.

[Robinson JG. Clinical Lipid Management;455a] Alirocumab (Praluent, Regeneron) and evolocumab (Repatha, Amgen) are the two mAbs currently approved by the FDA; both received approval in 2015.

A European green light for Praluent would put the closely watched so-called PCSK9 drug two months behind Amgen's rival product Repatha, which was formally approved by the European Commission on ...